As rTs-MIF does not directly target the pathways associated with adverse gastrointestinal, neurological, or cardiovascular effects commonly observed with current anti-obesity drugs, it is expected to have a lower risk of long-term side effects [26]. The gene discussed is MIF; the disease is Obesity.